The drugmaker is adamant the deceptive practices not only jeopardize patient well-bein, but also compromise the credibility of their FDA-approved Semaglutide medicines.
The maker of popular weight loss drug Ozempic is fighting back against copycats of the drug popping up nationwide.
Novo Nordisk has initiated legal proceedings against a range of entities – encompassing medical spas, weight loss clinics and online pharmacies – in a concerted effort to curb the sale and promotion of counterfeit drugs that claim to replicate the effects of Ozempic. "The danger is when people start to acquire these medications, either through social media or through retail pharmacies, that are not going through either their insurance or medical professional," said Dr. Rabia De Latour, a gastroenterologist and assistant professor in the Department of Medicine at the NYU Grossman School of Medicine.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
The back and forth on Berberine, the alleged 'Nature's Ozempic'Scripps News examines the dietary supplement touted on social media, but doctors advise against relying on it for weight loss.
Consulte Mais informação »
Ozempic, Weight-Loss Drugs Carry Costly, Complicated LogisticsOzempic, Weight-Loss Drugs Carry Costly, Complicated Logistics
Consulte Mais informação »
FDA Approves First RSV Vaccine For Kids—Given To Pregnant Moms—Here’s What To KnowRSV infects nearly every child by the time they reach 2 and can cause serious, potentially fatal, illness.
Consulte Mais informação »
On Abortion Pills, Federal Appeals Court Prescribes Justice for FDAAmericans concerned about the safety, health, and welfare of women and girls in this country received welcome news last week.
Consulte Mais informação »
Regeneron shares climb after FDA approval of macular degeneration treatmentShares of Regeneron Pharmaceuticals Inc. gained 1.4% premarket on Monday after the company said late Friday that the U.S. Food and Drug Administration had...
Consulte Mais informação »
Neurocrine Biosciences price target raised at Oppenheimer after FDA approves movement disorder treatmentNeurocrine Biosciences Inc. said Friday that the U.S. Food and Drug Administration has approved Ingrezza for treatment of an involuntary movement disorder...
Consulte Mais informação »